DOI: https://doi.org/10.22141/2224-0713.7.93.2017.116554

The modern view of the multiple sclerosis relapses treatment

G.G. Shkilnyuk, A.A. Bogdan, N.N. Burova, G.V. Kataeva, N.A. Samoilova, I.D. Stoliarov

Abstract


In spite of decreasing incidence of multiple sclerosis relapses in disease-modifying treatment, the problem of relapses treatment is still actual. Every relapse contributes to stable neurological deficiency and, hence, the progress of invalidization. It should be noted, that it is not always possible to definitely evaluate the activity of disease because of the variable magnetic resonance picture: some focuses disappear or reduce, at the same time other focuses appear or increase. In this case, the use of magnetic resonance spectroscopy is advisable. Magnetic resonance spectroscopy helps to evaluate the activity of disease at the early stage and to assess the biochemical and neurophysiological signs of demyelination. We present the description of a difficult clinical case of the multiple sclerosis relapse and the evaluation of the metabolic response on the treatment by means of the magnetic resonance spectroscopy.
Hence, the treatment of multiple sclerosis relapses is very important because it helps to delay the invalidization. It is necessary to evaluate accurately all risks and advantages of every type of relapse treatment.


Keywords


multiple sclerosis; relapses; magnetic resonance spectroscopy

References


Гусев Е.И., Бойко А.Н., Столяров И.Д. Рассеянный склероз: справочник терминов. — М.: Здоровье человека, 2015. — 436 с.

Hilas O., Patel P.N., Lam S. Disease modifying agents for multiple sclerosis // Open Neurol. J. — 2010. — 26(4). — P. 15-24.

Jacobs L.D., Cookfair D.L., Rudick R.A et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) // Ann. Neurol. — 1996. — 39(3). — P. 285-294.

Johnson K.P., Brooks B.R., Cohen J.A. et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group // Neurology. — 1995. — 45(7). — P. 1268-1276.

Бойко А.Н., Степанова И.О., Шмидт Т.Е. Методические рекомендации. Ведение больных с рассеянным склерозом / Под ред. Н.Н. Спирина. — М.: Здоровье человека, 2015. — 68 с.

Frohman E.M., Shah A., Eggenberger E. et al. Corticosteroids for multiple sclerosis: I. Application for treating exacerbations // Neurotherapeutics. — 2007. — № 4. — P. 618-62.

Miller D.H., Frank J.A. Magnetic resonance imaging techniques to monitor short term evolution of multiple sclerosis and to use in preliminary trials // J. Neurol. Neurosurg. Psychiatry. — 1998. — 64(1). — P. 44-46.

Трофимова Т.Н., Тотолян Н.А., Пахомов А.В. Лучевая диагностика рассеянного склероза. — СПб.: ЭЛБИ-СПб, 2010. — 128 с.

Жулев Н.М., Скоромец A.A., Трофимова Т.Н., Тотолян H.A. Современная диагностика рассеянного склероза. — СПб., 1998. — 28 с.

Kermode A.G., Thompson A.J., Tofts P. et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis // Pathogenetic and clinical implications (Brain.). — 1990. — 113(Pt. 5). — P. 1477-89.

Wallace C.J., Seland T.P., Fong T.C. Multiple sclerosis: the impact of MR imaging // Am. J. Roentgenol. — 1992. — 158(4). — P. 849-857.

Arnold D.L., Matthews P.M., Francis G.S. et al. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques // Ann. Neurol. — 1992. — 31(3). — P. 235-241.

Mader I., Roser W., Kappos L. et al. Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study // Am. J. Neuroradiol. — 2000. — 21(7). — P. 1220-1227.

Ingle G.T., Miller D.H., Stevenson V.L. et al. Two-year follow-up study of primary and transitional progressive multiple sclerosis // Mult. Scler. — 2002. — 8(2). — P. 108-114.

Sajja B.R., Wolinsky J.S., Narayana P.A. Proton magnetic resonance spectroscopy in multiple sclerosis // Neuroimaging Clin. N. Am. — 2009. — 19(1). — P. 45-58.

Rovira À., Auger C., Alonso J. Magnetic resonance monitoring of lesion evolution in multiple sclerosis // Ther. Adv. Neurol. Disord. — 2013. — 6(5). — P. 298-310.

Miller H., Newell D.J., Ridley A. Multiple sclerosis. Treatment of acute exacerbations with corticotrophin (A.C.T.H.) // Lancet. — 1961. — 18. — P. 1120-2.

Lublin F.D., Baier M., Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis // Neurology. — 2003. — 61. — P. 1528-1532.

Berkovich R. Treatment of acute relapses in multiple sclerosis // Neurotherapeutics. — 2013. — 10(1). — P. 97-105.




Copyright (c) 2017 INTERNATIONAL NEUROLOGICAL JOURNAL

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта